Reshape Lifesciences Inc RSLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RSLS is a good fit for your portfolio.
News
-
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
-
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
-
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
-
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
-
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
-
ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.17–0.18
- 52-Week Range
- $0.14–2.80
- Bid/Ask
- $0.16 / $0.18
- Market Cap
- $3.91 Mil
- Volume/Avg
- 64,150 / 527,403
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 31
Valuation
|
Metric
|
RSLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.59 |
Price/Sales | 0.11 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RSLS
|
|---|---|
Quick Ratio | 1.63 |
Current Ratio | 2.73 |
Interest Coverage | — |
Quick Ratio
RSLS
Profitability
|
Metric
|
RSLS
|
|---|---|
Return on Assets (Normalized) | −111.92% |
Return on Equity (Normalized) | −231.98% |
Return on Invested Capital (Normalized) | −223.45% |
Return on Assets
RSLS
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Tzdfftgt | Kwmhcwz | $185.8 Bil | |
SYK
| Stryker Corp | Bfvldpxj | Hcjr | $124.7 Bil | |
MDT
| Medtronic PLC | Hlzkjxyl | Qzpvj | $105.2 Bil | |
BSX
| Boston Scientific Corp | Yfmkzyh | Rrzrmd | $99.0 Bil | |
EW
| Edwards Lifesciences Corp | Dqmhqpgnn | Mrkxwy | $52.3 Bil | |
DXCM
| DexCom Inc | Ymshxkbby | Mfq | $52.1 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Pqqgdtrm | Mpph | $24.8 Bil | |
ALGN
| Align Technology Inc | Nnsmptr | Qmgrcy | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Tphgrjhl | Ltvncn | $18.5 Bil | |
PODD
| Insulet Corp | Cbcxprbmm | Rdshdgr | $11.5 Bil |